# Cursor (Grok 4.6 high) — verificación de ronda 8 (los reportes ya corregidos)

`agent -p --mode ask`, 30-ago-2026. Mismo brief que Codex.

The edits reintroduced the same rows-versus-genes error you just corrected, and they applied the new benchmark numbers to the dominant artefact you say you do not stand behind.

## 1. Contradictions the edits introduced

**1. “Rank 2 of 3,139 genes under AR” is a chimera of row-rank and gene-count.**

After the 4,565 correction, Track 1 now says:

> “BUB1B ranked 2nd of 3,139 genes under the autosomal recessive model”
> “0.5871 (rank 1, AD) and 0.5538 (rank 2, AR) against 0.2137 for the third-ranked gene”

The results file, describing the same run, says:

> “FANCD2 is the gene that actually came second in our real Track 1 run”
> Honest form: “rank 1 of 3,139 genes, of which 257 scored above zero and 32 scored ≥ 0.01.”

Those cannot all be true. Rank 1 = BUB1B AD 0.5871 and rank 2 = BUB1B AR 0.5538 means **BUB1B occupies two rows**. 0.2137 is then the third **row** and the second **gene**. Calling it “the third-ranked gene” and calling AR “rank 2 of 3,139 genes” repeats the 4,565 mistake with a new numerator. Unique-gene rank of BUB1B is **1 of 3,139**. Row-rank of the AR model is **2 of N rows**, not of 3,139 genes. Under AR rows only, BUB1B is almost certainly rank 1, not rank 2.

The Q12 abstract copies the chimera: “ranked 2nd of 3,139 genes under the recessive model.”

**2. The result you stand behind is 0.5538 / AR; every new number uses 0.5871 / AD.**

> “The result we stand behind is rank 2, not rank 1.”

Replacement phenotype comparison:

> “0.5871 with the patient’s eight terms, 0.4187 with five verified-unrelated terms, Δ = 0.1684”

Benchmark: “Our 0.5871 is above all seven, **by 0.025**.” ClinVar strip: 0.5871 → 0.5743. Abstract: “0.058–0.562 against our 0.587.” Leave-one-out: “BUB1B remained rank 1 in all eight.” Clean control: “top of the ranking, score 0.4187 on the **dominant** row.” Results §5: the winning BUB1B row in every construct is AD.

The 24% withdrawal was replaced with a finite difference on the artefact. You never report the AR score (0.5538) under the clean unrelated HPO set, under GIAB, or after stripping ClinVar. The controls that “argue against us” and the benchmark that “shows three things” are all measurements of the row you disclaim.

**3. A share of a non-linear combined score is undefined — except for ClinVar, where it is 2.2%.**

Phenotype, after the edit:

> “We do **not** convert that delta into a percentage of the score: Exomiser combines phenotype and variant evidence non-linearly … so a share is not defined.”

Results §0.2(a): “converting it to a percentage is invalid regardless.”

ClinVar, same documents:

> “Removing ClinVar entirely costs 0.0128 — **2.2% of the combined score**”
> Abstract: “**0.0128, 2.2% of the score**”
> Results §0.1: “the answer is **2.2%**, not 88%”
> Results §0.2(b): “worth **0.0128 — 2.2% of the score**”

0.0128/0.5871 = 2.18%. That is the same operation you just forbade for 0.1684/0.5871 (the retracted 28.7%). “Costs 0.0128” is supported. “2.2% of the score” is the framing error you withdrew, reattached to a different component.

**4. The abstract re-states a claim the results file still lists as retracted.**

Results §0.1: “The combined score is a property of the two alleles and the phenotype, not of the genome” — **RETRACTED as over-stated**, restated in §2 only given that none of the three backgrounds retains its own BUB1B allele, and “not three independent replications of the Δ = 0.1684 contrast: it is one deterministic computation run three times.”

Abstract: “reproduces 0.5871 and 0.4187 to four decimals — **the score follows the alleles and the query, not the genome**.”

Track 1 body asks “Is the score a property of the patient’s genome?” and answers with the four-decimal invariance, without the §2 “given.” The retraction was applied to `RESULTADOS.md` and then undone in the two places a judge will read.

**5. “61 runs … shows three things” versus Experiment A still open.**

Abstract: “A benchmark pre-registered … **61 runs** … **shows** three things.”

Results header: “Experiment A tier 2 (30 × 1000 Genomes) **is still running and is marked open**.” Scoreboard: P-A **OPEN**. Body of Track 1 is more careful (“cut the design from ~150 runs to 61”). The abstract treats the design size as completed evidence.

**6. “One of seven pre-registered predictions was contrary” versus “not evaluable as locked.”**

Track 1: “One of seven pre-registered predictions was contrary to its predicted direction and is reported as such.”

Results §4 / §6: P-B3 is “**not evaluable as locked**”; the corrected cells are “post-amendment exploratory, not confirmatory,” and “we are not cashing it as evidence of discrimination.” “Contrary” is true of the exploratory construct. Counting it as one of seven resolved predictions is not what `RESULTADOS.md` does (6 resolved, P-A open, P-B3 not evaluable as locked).

---

## 2. Still over-stated after the edit

**7. “It would have been reached for a nonsense allele that no database had ever seen.”**

X2/X3 use `chr15:40212550`, a **ClinVar record with no CLNSIG**, not a novel allele absent from ClinVar. X1 shows the missense can be absent from ClinVar (contribution 0.0000). The nonsense was never tested as database-absent. “Unclassified / not whitelisted” is what you measured. “No database had ever seen” is not.

**8. “Stripping both ClinVar classifications from this case’s architecture.”**

You cannot strip 533901. You substituted a different stop-gain at a different position. Variant scores staying at 1.0000 makes the substitution informative for saturation of the variant term. It is not a knockdown of this case’s ClinVar field. Rank-unchanged was measured in HG002/HG005, not in the patient’s genome.

**9. “The phenotype selects the recessive MVA interpretation over the dominant artefact.”**

Exomiser still ranks AD above AR (0.5871 > 0.5538). Phenotype maps disease names onto models; a human standing behind rank 2 selects the diagnosis. Leave-one-out and the unrelated-HPO control still report **rank 1**. The abstract’s “selects the recessive interpretation over the dominant artefact” reads as if the pipeline preferred AR. It did not.

**10. Q4/Q5 still say two manual decisions and “No variant was added, removed or re-ranked on intuition,”** while the new Result section is an explicit demotion of the top row. The panel convergence can justify submitting the compound-het pair; it does not make “not re-ranked” accurate once you write “the result we stand behind is rank 2, not rank 1.”

---

## 3. Arithmetic and denominators

Checked against the results file:

| Claim | Calculation | Verdict |
|---|---|---|
| 0.5871 − 0.5619 = 0.025 | 0.0252 | OK as 0.025; results’ 4.3% is 4.29% |
| 0.5871 − 0.5743 = 0.0128 | exact | OK |
| 2.2% | 0.0128/0.5871 = 2.18% | Rounding OK; **the share is the problem**, see #3 |
| 0.5871 − 0.4187 = 0.1684 | exact | OK |
| 0.5538/0.2137 = 2.59× | 2.5915 | OK |
| 0.5871/0.2137 = 2.75× | 2.747 | OK |
| 3,139 / 257 / 32 | internally consistent | OK as unique-gene counts |
| Results’ “remaining 4,262 rows” | 4,565 − 4,262 = **303** scoring rows from 257 genes | OK as rows; do not equate 4,262 with 3,139−257 |
| 10,911 bp | 40220612 − 40209701 = 10911 | OK for the planted T>A POS |
| 0.64 and 0.006 | 1.0×10⁻⁴ × 6404 = 0.640; 9.0×10⁻⁷ × 6404 = 0.00576 | OK; table AF 9.98×10⁻⁵ gives 0.639 |
| ~3×10⁶ haplotypes for 95% | ln(0.05)/8.99×10⁻⁷ ≈ 3.33×10⁶ | OK as order of magnitude |
| 0.34% phase penalty | 0.9339−0.9305 = 0.0034 = **0.34 percentage points**; relative is **0.36%** | Wrong if read as a relative penalty; same non-linear-share issue as 2.2% |
| 1.4-SD floor | 0.005/0.0035 = 1.43 | OK |
| 7–16× | 14/2=7, 16/1=16 | OK |
| Abstract word count | 496 | OK |

**11.** Track 1 ClinVar coordinate `NC_000015.10:40220611:T:A` versus results `chr15:40220612 T>A`. One-base clash. If the child’s missense is at 40220611, the distance is 10,910 intervening bases, not 10,911. Minor, but it is in the two documents you pasted.

---

## 4. The abstract

496 words, confirmed. Two problems a judge hits immediately:

- It leads with **rank 2 of 3,139** (AR) and then calls **0.587** “our” score (AD). That is finding 1+2 in 500 words.
- “The phenotype selects the recessive MVA interpretation” and “the score follows the alleles and the query, not the genome” are the two overshoots most likely to be quoted.

Unsupported or misleading relative to the body/results: “61 runs … shows”; “2.2% of the score”; “no database had ever seen” is not in the abstract, but “stripping both ClinVar classifications” is, and a judge will hear “we deleted ClinVar from this case.”

Missing that a judge needs, if you cut to make room:

1. That 0.5871 is the **dominant-row** score, and unique-gene rank is 1.
2. That P-A is a **0.025 near-miss on a null biased in your favour**, and tier 2 is open — the body has this; the abstract’s “shows three things” buries it.
3. That the ClinVar number is a **substitute unclassified nonsense**, not 533901 with the star removed.
4. That without ClinVar the Exomiser ACMG call on this architecture is **LIKELY_PATHOGENIC**, not PATHOGENIC (results §3.2 table). Rank is unchanged; the classification is not.

What I would cut: the 61-run / two-reviewer process clause; “2.2% of the score”; “the score follows the alleles and the query, not the genome”; “rank 2 of 3,139 genes.” Those four buy the hedges above.

---

## 5. Is the corrected ClinVar statement safe?

No. “The truncating consequence carries the ranking, not the database record” outruns one substitute stop-gain in two backgrounds. You isolated the whitelist/PP5 on **that** nonsense, not on 533901, and not on a ClinVar-absent nonsense. Variant-score identity (1.0000) is the strong measurement. Combined-score drop 0.0128 and rank-stability in 2/2 non-inert backgrounds are the rest. ACMG P → LP is part of the same experiment and is omitted from Track 1’s table.

Sentence I would submit:

> Holding gene, partner allele and phenotype fixed, an unclassified (non-whitelisted) BUB1B `stop_gained` at `chr15:40212550` scores 1.0000 on the variant term — identical to this case’s ClinVar P/LP nonsense — and the combined score falls from 0.5871 to 0.5743 in both backgrounds tested, without leaving the top position. We did not strip ClinVar from the child’s own allele; this is a same-consequence substitute, and the 0.0128 movement is the whitelist plus PP5 on that substitute (ACMG PATHOGENIC → LIKELY_PATHOGENIC). It is evidence that `stop_gained` saturates the variant term here, not that a nonsense never seen by any database would have been ranked the same, and not a fraction of the combined score.

---

## 6. Uncorrected in the report, now contradicted by the results

**12. Results §5 was the sentence you were told to put in the report. It is still not there.**

> “The pipeline’s top-ranked row for BUB1B is a dominant single-allele model, not the recessive compound-heterozygous model the diagnosis rests on; and the compound-heterozygous call is invariant to whether the two alleles are on the same chromosome. The recessive interpretation is supplied by the inheritance model and the phenotype, not by the retrieval.”

Track 1 now says AD rank 1 is an artefact of **this** truncating allele, and Q9 still opens “Yes, and it did so without being told to.” The benchmark says AD is the winning BUB1B row in **every** construct, including C-lo (two VUS missense, no truncation, 0.1120). “It wins the top slot **because** a single truncating allele saturates the variant term of the dominant model” cannot be the general mechanism if AD also wins when there is no truncation. The LoF explains **why this case’s AD score is 0.5871**, not **why AD outranks AR**. That is the claim from before the benchmark existed that the results now contradict, and the §5 paragraph that was supposed to replace it was not copied into Track 1.

Q9’s cis test (0.34%) and the “we stand behind rank 2” sentence are adjacent to this and do not substitute for it: a judge can still leave Q3 believing Exomiser retrieved compound heterozygosity as the top result.

